Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis

Elisabetta Miserocchi, Giulio Modorati, Luigi Berchicci, Irene Pontikaki, Pierluigi Meroni, Valeria Gerloni

Research output: Contribution to journalArticle

Abstract

Background/aims: To evaluate retrospectively the long-term efficacy of rituximab in patients with severe juvenile idiopathic arthritis ( JIA)-associated uveitis. Methods: Eight patients (15 eyes) with severe and longstanding JIA uveitis, who had an inadequate response in controlling uveitis to one or more biologic agents including tumour necrosis factor blockers and abatacept, received rituximab therapy. Rituximab was given at a dose of 1000 mg per infusion on days 1 and 15 and then every 6 months. Clinical responses to treatment, including decrease in uveitis activity, visual acuity changes, reduction of concomitant local and systemic corticosteroid and/or immunosuppressants, and occurrence of adverse events, were assessed. Results: Eight patients with a mean ± SD age of 22.8 ± 5.5 years were treated. The mean ocular disease duration was 17.7 years; the mean ± SD follow-up time on rituximab was 44.75 ± 4.9 months; and the mean number of rituximab infusions received was 8.75 (range 6-12). All patients achieved complete control of uveitis, but in two patients rituximab was discontinued due to inefficacy in treating arthritis. The decrease in uveitis activity was evident 4-5 months after the first infusion. Systemic corticosteroids and immunosuppressants used in association with rituximab were discontinued in five patients at the end of follow-up. None of the patients experienced visual worsening during the follow-up. No drug-related complications were encountered. Conclusions: Rituximab may be a promising effective treatment option for refractory uveitis associated with JIA leading to long-term quiescence of uveitis, particularly for patients who have not previously responded to other biologic therapies.
Original languageEnglish
Pages (from-to)782 - 786
Number of pages5
JournalBritish Journal of Ophthalmology
Volume100
Issue number6
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Juvenile Arthritis
Uveitis
Therapeutics
Immunosuppressive Agents
Adrenal Cortex Hormones
Biological Therapy
Eye Diseases
Rituximab
Biological Factors
Visual Acuity
Arthritis
Tumor Necrosis Factor-alpha
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. / Miserocchi, Elisabetta; Modorati, Giulio; Berchicci, Luigi; Pontikaki, Irene; Meroni, Pierluigi; Gerloni, Valeria.

In: British Journal of Ophthalmology, Vol. 100, No. 6, 01.06.2016, p. 782 - 786.

Research output: Contribution to journalArticle

Miserocchi, Elisabetta ; Modorati, Giulio ; Berchicci, Luigi ; Pontikaki, Irene ; Meroni, Pierluigi ; Gerloni, Valeria. / Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. In: British Journal of Ophthalmology. 2016 ; Vol. 100, No. 6. pp. 782 - 786.
@article{9fa96981bd7f40ae8b8e87b4b94492e2,
title = "Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis",
abstract = "Background/aims: To evaluate retrospectively the long-term efficacy of rituximab in patients with severe juvenile idiopathic arthritis ( JIA)-associated uveitis. Methods: Eight patients (15 eyes) with severe and longstanding JIA uveitis, who had an inadequate response in controlling uveitis to one or more biologic agents including tumour necrosis factor blockers and abatacept, received rituximab therapy. Rituximab was given at a dose of 1000 mg per infusion on days 1 and 15 and then every 6 months. Clinical responses to treatment, including decrease in uveitis activity, visual acuity changes, reduction of concomitant local and systemic corticosteroid and/or immunosuppressants, and occurrence of adverse events, were assessed. Results: Eight patients with a mean ± SD age of 22.8 ± 5.5 years were treated. The mean ocular disease duration was 17.7 years; the mean ± SD follow-up time on rituximab was 44.75 ± 4.9 months; and the mean number of rituximab infusions received was 8.75 (range 6-12). All patients achieved complete control of uveitis, but in two patients rituximab was discontinued due to inefficacy in treating arthritis. The decrease in uveitis activity was evident 4-5 months after the first infusion. Systemic corticosteroids and immunosuppressants used in association with rituximab were discontinued in five patients at the end of follow-up. None of the patients experienced visual worsening during the follow-up. No drug-related complications were encountered. Conclusions: Rituximab may be a promising effective treatment option for refractory uveitis associated with JIA leading to long-term quiescence of uveitis, particularly for patients who have not previously responded to other biologic therapies.",
author = "Elisabetta Miserocchi and Giulio Modorati and Luigi Berchicci and Irene Pontikaki and Pierluigi Meroni and Valeria Gerloni",
year = "2016",
month = "6",
day = "1",
doi = "10.1136/bjophthalmol-2015-306790",
language = "English",
volume = "100",
pages = "782 -- 786",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis

AU - Miserocchi, Elisabetta

AU - Modorati, Giulio

AU - Berchicci, Luigi

AU - Pontikaki, Irene

AU - Meroni, Pierluigi

AU - Gerloni, Valeria

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Background/aims: To evaluate retrospectively the long-term efficacy of rituximab in patients with severe juvenile idiopathic arthritis ( JIA)-associated uveitis. Methods: Eight patients (15 eyes) with severe and longstanding JIA uveitis, who had an inadequate response in controlling uveitis to one or more biologic agents including tumour necrosis factor blockers and abatacept, received rituximab therapy. Rituximab was given at a dose of 1000 mg per infusion on days 1 and 15 and then every 6 months. Clinical responses to treatment, including decrease in uveitis activity, visual acuity changes, reduction of concomitant local and systemic corticosteroid and/or immunosuppressants, and occurrence of adverse events, were assessed. Results: Eight patients with a mean ± SD age of 22.8 ± 5.5 years were treated. The mean ocular disease duration was 17.7 years; the mean ± SD follow-up time on rituximab was 44.75 ± 4.9 months; and the mean number of rituximab infusions received was 8.75 (range 6-12). All patients achieved complete control of uveitis, but in two patients rituximab was discontinued due to inefficacy in treating arthritis. The decrease in uveitis activity was evident 4-5 months after the first infusion. Systemic corticosteroids and immunosuppressants used in association with rituximab were discontinued in five patients at the end of follow-up. None of the patients experienced visual worsening during the follow-up. No drug-related complications were encountered. Conclusions: Rituximab may be a promising effective treatment option for refractory uveitis associated with JIA leading to long-term quiescence of uveitis, particularly for patients who have not previously responded to other biologic therapies.

AB - Background/aims: To evaluate retrospectively the long-term efficacy of rituximab in patients with severe juvenile idiopathic arthritis ( JIA)-associated uveitis. Methods: Eight patients (15 eyes) with severe and longstanding JIA uveitis, who had an inadequate response in controlling uveitis to one or more biologic agents including tumour necrosis factor blockers and abatacept, received rituximab therapy. Rituximab was given at a dose of 1000 mg per infusion on days 1 and 15 and then every 6 months. Clinical responses to treatment, including decrease in uveitis activity, visual acuity changes, reduction of concomitant local and systemic corticosteroid and/or immunosuppressants, and occurrence of adverse events, were assessed. Results: Eight patients with a mean ± SD age of 22.8 ± 5.5 years were treated. The mean ocular disease duration was 17.7 years; the mean ± SD follow-up time on rituximab was 44.75 ± 4.9 months; and the mean number of rituximab infusions received was 8.75 (range 6-12). All patients achieved complete control of uveitis, but in two patients rituximab was discontinued due to inefficacy in treating arthritis. The decrease in uveitis activity was evident 4-5 months after the first infusion. Systemic corticosteroids and immunosuppressants used in association with rituximab were discontinued in five patients at the end of follow-up. None of the patients experienced visual worsening during the follow-up. No drug-related complications were encountered. Conclusions: Rituximab may be a promising effective treatment option for refractory uveitis associated with JIA leading to long-term quiescence of uveitis, particularly for patients who have not previously responded to other biologic therapies.

UR - http://www.scopus.com/inward/record.url?scp=84942134606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942134606&partnerID=8YFLogxK

U2 - 10.1136/bjophthalmol-2015-306790

DO - 10.1136/bjophthalmol-2015-306790

M3 - Article

VL - 100

SP - 782

EP - 786

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 6

ER -